KSE100 34408.05  ▲ Increased By 386.08 (1.13%)
KSE30 15071.48  ▲ Increased By 215.83 (1.45%)
BR100 3542.91  ▲ Increased By 42.56 (1.22%)
BR30 18504.96  ▲ Increased By 58.77 (0.32%)

Business Recorder Logo

Jun 03, 2020 PRINT EDITION

ZURICH: The European Medicine Agency's Committee for Medicinal Products for Human Use has recommended EU approval of Roche's cancer immunotherapy Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer, the Basel company said on Friday.

The EMA also adopted a positive opinion of Tecentriq in combination with chemotherapy as an initial treatment for the most common form of advanced lung cancer - metastatic non-squamous non-small cell lung cancer - Roche said in a separate statement.

Copyright Reuters, 2019